- Home
- CRBP vs RNAC Comparison
CRBP vs RNAC Comparison
Compare CRBP & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | RNAC |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 168.3M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CRBP | RNAC |
|---|---|---|
| Price | $10.59 | $6.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $45.60 | $34.00 |
| AVG Volume (30 Days) | ★ 237.0K | 166.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $6.10 | $5.60 |
| 52 Week High | $20.56 | $14.56 |
Technical Indicators
Market Signals| Indicator | CRBP | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 55.48 |
| Support Level | $7.91 | $6.54 |
| Resistance Level | $10.62 | $7.81 |
| Average True Range (ATR) | 0.66 | 0.45 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 63.67 | 70.15 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.